Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?

The company defends its cancer strategy, and says it's not a me-too developer.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.